30 related articles for article (PubMed ID: 14565319)
1. Binding isotope effects: boon and bane.
Schramm VL
Curr Opin Chem Biol; 2007 Oct; 11(5):529-36. PubMed ID: 17869163
[TBL] [Abstract][Full Text] [Related]
2. Role of histidine-85 in the catalytic mechanism of thymidine phosphorylase as assessed by targeted molecular dynamics simulations and quantum mechanical calculations.
Mendieta J; Martín-Santamaría S; Priego EM; Balzarini J; Camarasa MJ; Pérez-Pérez MJ; Gago F
Biochemistry; 2004 Jan; 43(2):405-14. PubMed ID: 14717594
[TBL] [Abstract][Full Text] [Related]
3. Nucleophilic participation in the transition state for human thymidine phosphorylase.
Birck MR; Schramm VL
J Am Chem Soc; 2004 Mar; 126(8):2447-53. PubMed ID: 14982453
[TBL] [Abstract][Full Text] [Related]
4. The role of phosphate in the action of thymidine phosphorylase inhibitors: Implications for the catalytic mechanism.
Jain HV; Rasheed R; Kalman TI
Bioorg Med Chem Lett; 2010 Mar; 20(5):1648-51. PubMed ID: 20138520
[TBL] [Abstract][Full Text] [Related]
5. Kinetic analysis of novel multisubstrate analogue inhibitors of thymidine phosphorylase.
Balzarini J; Degrève B; Esteban-Gamboa A; Esnouf R; De Clercq E; Engelborghs Y; Camarasa MJ; Pérez-Pérez MJ
FEBS Lett; 2000 Oct; 483(2-3):181-5. PubMed ID: 11042277
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationship of 2,4,5-trioxoimidazolidines as inhibitors of thymidine phosphorylase.
Rajabi M; Mansell D; Freeman S; Bryce RA
Eur J Med Chem; 2011 Apr; 46(4):1165-71. PubMed ID: 21324566
[TBL] [Abstract][Full Text] [Related]
7. Towards new thymidine phosphorylase/PD-ECGF inhibitors based on the transition state of the enzyme reaction.
Priego EM; Mendieta J; Gago F; Balzarini J; De Clercq E; Camarasa MJ; Pérez-Pérez MJ
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):951-3. PubMed ID: 14565319
[TBL] [Abstract][Full Text] [Related]
8. The rôle of thymidine phosphorylase/PD-ECGF in cancer chemotherapy: a chemical perspective.
Cole C; Foster AJ; Freeman S; Jaffar M; Murray PE; Strafford IJ
Anticancer Drug Des; 1999 Oct; 14(5):383-92. PubMed ID: 10766293
[TBL] [Abstract][Full Text] [Related]
9. Enzymatic transition states: thermodynamics, dynamics and analogue design.
Schramm VL
Arch Biochem Biophys; 2005 Jan; 433(1):13-26. PubMed ID: 15581562
[TBL] [Abstract][Full Text] [Related]
10. Thymidine phosphorylase inhibitors: recent developments and potential therapeutic applications.
Pérez-Pérez MJ; Priego EM; Hernández AI; Camarasa MJ; Balzarini J; Liekens S
Mini Rev Med Chem; 2005 Dec; 5(12):1113-23. PubMed ID: 16375757
[TBL] [Abstract][Full Text] [Related]
11. Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy.
Liekens S; Bronckaers A; Pérez-Pérez MJ; Balzarini J
Biochem Pharmacol; 2007 Dec; 74(11):1555-67. PubMed ID: 17572389
[TBL] [Abstract][Full Text] [Related]
12. Enzyme inhibitors as chemical tools to study enzyme catalysis: rational design, synthesis, and applications.
Hiratake J
Chem Rec; 2005; 5(4):209-28. PubMed ID: 16041744
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
